These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 19047118

  • 1. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
    Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.
    Clin Cancer Res; 2008 Dec 01; 14(23):7884-95. PubMed ID: 19047118
    [Abstract] [Full Text] [Related]

  • 2. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ.
    J Clin Oncol; 2007 Aug 01; 25(22):3230-7. PubMed ID: 17664471
    [Abstract] [Full Text] [Related]

  • 3. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.
    N Engl J Med; 2008 Oct 23; 359(17):1757-65. PubMed ID: 18946061
    [Abstract] [Full Text] [Related]

  • 4. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
    Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ.
    Pharmacogenet Genomics; 2006 Jul 23; 16(7):475-83. PubMed ID: 16788380
    [Abstract] [Full Text] [Related]

  • 5. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3712-8. PubMed ID: 17704420
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF.
    Clin Ther; 2005 Jun 20; 27(6):684-94. PubMed ID: 16117976
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
    Li YH, Wang F, Shen L, Deng YM, Shao Q, Feng F, An X, Wang FH, Wang ZQ, Xu RH, Shao JY.
    Clin Cancer Res; 2011 Jan 15; 17(2):382-90. PubMed ID: 20884623
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bisonni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G, Magnani M.
    J Clin Oncol; 2008 Mar 20; 26(9):1427-34. PubMed ID: 18349392
    [Abstract] [Full Text] [Related]

  • 13. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.
    Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson PM, Pohl A, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.
    Clin Cancer Res; 2010 Nov 15; 16(22):5591-602. PubMed ID: 20935157
    [Abstract] [Full Text] [Related]

  • 14. Cetuximab for the treatment of colorectal cancer.
    Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ.
    N Engl J Med; 2007 Nov 15; 357(20):2040-8. PubMed ID: 18003960
    [Abstract] [Full Text] [Related]

  • 15. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O.
    Oncologist; 2009 Jan 15; 14(1):22-8. PubMed ID: 19144677
    [Abstract] [Full Text] [Related]

  • 16. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Klinghammer K, Knödler M, Schmittel A, Budach V, Keilholz U, Tinhofer I.
    Clin Cancer Res; 2010 Jan 01; 16(1):304-10. PubMed ID: 20028750
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
    Sastre J, Aranda E, Grávalos C, Massutí B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Díaz-Rubio E, Hidalgo M.
    Crit Rev Oncol Hematol; 2011 Jan 01; 77(1):78-84. PubMed ID: 20042346
    [Abstract] [Full Text] [Related]

  • 20. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
    Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G.
    Clin Cancer Res; 2011 Oct 15; 17(20):6531-41. PubMed ID: 21890455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.